Who are RASS inhibitors and/or RAS blockers's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rass-inhibitors-and-or-ras-blockers.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

RASS inhibitors and/or RAS blockers — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RASS inhibitors and/or RAS blockers (RASS inhibitors and/or RAS blockers) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: RASS inhibitor / RAS blocker (ACE inhibitor, ARB, direct renin inhibitor, or aldosterone antagonist). Area: Cardiovascular.

phase 3 RASS inhibitor / RAS blocker (ACE inhibitor, ARB, direct renin inhibitor, or aldosterone antagonist) Renin-angiotensin-aldosterone system components (ACE, angiotensin II receptor type 1, renin, or aldosterone receptor) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

RASS inhibitors and/or RAS blockers (RASS inhibitors and/or RAS blockers) — Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia. RASS inhibitors and RAS blockers suppress the renin-angiotensin-aldosterone system to reduce vasoconstriction, lower blood pressure, and decrease sodium retention.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
RASS inhibitors and/or RAS blockers TARGET	RASS inhibitors and/or RAS blockers	Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia	phase 3	RASS inhibitor / RAS blocker (ACE inhibitor, ARB, direct renin inhibitor, or aldosterone antagonist)	Renin-angiotensin-aldosterone system components (ACE, angiotensin II receptor type 1, renin, or aldosterone receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (RASS inhibitor / RAS blocker (ACE inhibitor, ARB, direct renin inhibitor, or aldosterone antagonist) class)

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). RASS inhibitors and/or RAS blockers — Competitive Intelligence Brief. https://druglandscape.com/ci/rass-inhibitors-and-or-ras-blockers. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab